Sharing some updates as I complete another trip around the sun

Nerandomilast Phase 3 clinical trial meets its primary goal in IPF

A Phase 3 clinical trial testing Boehringer Ingelheim’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the therapy outperformed a placebo at improving lung function or preventing its decline after a year, recently announced top-line data shows.

The need for pulmonary fibrosis awareness never ends

When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, the disease was a mystery to me. I’ve shared before that when my wife, Susan, and I left the clinic following my diagnosis, we began to search for information from the parking garage. That thirst for…

$15K award goes to researcher for work into IPF disease risk factors

A University of Colorado professor has won the 2024 Alton Ochsner Award Relating Smoking and Disease for his work into how genetic and environmental factors, including smoking, contribute to a person’s risk of idiopathic pulmonary fibrosis (IPF) — when the disease is due to unknown causes. The $15,000 prize…

Learning to live with both sleep apnea and pulmonary fibrosis

Living with pulmonary fibrosis is already a daunting challenge, but when coupled with a sleep disorder like sleep apnea, the burden becomes even heavier. Sleep apnea, a condition in which breathing repeatedly stops and starts during sleep, can significantly impact both sleep quality and overall health. For…

Phase 2b trial tests AP01, inhaled pirfenidone, in progressive PF

Avalyn Pharma has started a Phase 2b clinical trial testing the safety and efficacy of AP01, its investigational inhaled formulation of pirfenidone, in adults with progressive pulmonary fibrosis (PF). The MIST trial (NCT06329401) is expected to enroll 300 progressive PF patients, who will receive either one of…

Immune cells separate IPF, fibrotic hypersensitivity pneumonitis

Researchers have identified immune cell populations that could be used to help distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis (IPF), a study suggests. People with hypersensitivity pneumonitis, which is a rare type of pulmonary fibrosis (PF), show elevated levels of certain types of immune cells in the…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums